Data in SCLC patients were presented in May 2015 as preliminary results of an ongoing multi-cohort, phase Ib study of pembrolizumab in patients with PD-L1+ advanced solid tumors (Keynote 028). Here, CD274 is linked to small cell lung carcinoma.